Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 2.35%
Comtex SmarTrend(R) - Tue Dec 23, 4:06PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $69.01 to a high of $71.73. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $70.25 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 70.16 (+0.42)
SmarTrend Watching for Potential Rebound in Shares of Eli Lilly After 2.35% Loss
Comtex SmarTrend(R) - Tue Dec 23, 4:05PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $69.01 to a high of $71.73. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $70.25 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 70.16 (+0.42)
$72 Billion Pharma Company Gives Away Miracle Drug
Stephen Petranek - Daily Reckoning - Tue Dec 23, 11:13AM CST
This post $72 Billion Pharma Company Gives Away Miracle Drug appeared first on Daily Reckoning . Former editor-in-chief of Discover magazine Stephen Petranek has his eye on a special type of pharmaceutical company that has seen its stock price...
LLY: 70.16 (+0.42)
Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:50PM CST
Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone Lispro, for type I and type II diabetes.
BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), LLY: 70.16 (+0.42), MNKD: 5.68 (+0.18)
Eli Lilly to sell heartworm line for Novartis deal approval
AP - Mon Dec 22, 1:13PM CST
NEW YORK (AP) — Eli Lilly will sell its heartworm treatment for dogs to garner U.S. approval for its $5.4 billion acquisition of the animal health division belonging to Norvartis.
LLY: 70.16 (+0.42)
Lilly jettisons Sentinel line as a condition for clearance of Novartis deal
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:32AM CST
LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)
Lilly Announces Diabetes Research Partnership with University of Surrey
PR Newswire Europe - Mon Dec 22, 9:19AM CST
- The five-year collaboration with the UK public research university will focus on health outcomes for people with type 2 diabetes
LLY: 70.16 (+0.42)
Radius Health osteoporosis drug candidate successful in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 7:23AM CST
RDUS: 37.17 (+0.11), LLY: 70.16 (+0.42)
Drug Giants Face $65 Billion in Lost Sales as Insurers Attack Patents
Bruce Japsen, The Motley Fool - Motley Fool - Sun Dec 21, 8:01AM CST
By 2019, pharmaceutical companies face a major loss of $65 billion in sales due to patent expirations largely from brand name central nervous system drugs that are opening up to competition from cheaper generic copies. A new report from...
ESRX: 85.48 (-0.40), AZN: 70.44 (+0.26), LLY: 70.16 (+0.42)
Zoetis: Betting The Proverbial Farm?
Marshall Hargrave - at Seeking Alpha - Sat Dec 20, 7:15AM CST
ZTS: 43.84 (+0.87), ABT: 45.70 (-0.02), MRK: 57.46 (+0.25), LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)
7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends
Dividends4Life - at Seeking Alpha - Fri Dec 19, 9:11PM CST
MMM: 166.96 (+0.09), ABT: 45.70 (-0.02), GE: 25.83 (-0.05), PFE: 31.42 (-0.03), LLY: 70.16 (+0.42), O: 49.42 (+0.33), BA: 131.24 (+1.21)
Roche Drugs For Alzheimer's, Breast Cancer Disappoint
at Investor's Business Daily - Fri Dec 19, 10:31AM CST
Big Swiss pharma Roche (RHHBY) halted development of its Alzheimer's disease drug and reported mediocre results from a clinical trial of breast-cancer drug Kadcyla Friday, sending the stock down more than 6% in early trading on the stock market...
BIIB: 340.89 (+5.13), IMGN: 5.90 (+0.13), LLY: 70.16 (+0.42)
Lilly signs development deal for ultra-rapid insulin
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:50AM CST
LLY: 70.16 (+0.42)
Lilly to co-develop ultra-rapid insulin BioChaperone Lispro in partnership with Adocia
M2 - Fri Dec 19, 7:09AM CST
Healthcare company Eli Lilly and Company (NYSE:LLY) and Adocia (Euronext Paris:FR0011184241) jointly disclosed on Thursday a worldwide licensing collaboration to develop an ultra-rapid insulin, called BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes.
LLY: 70.16 (+0.42)
Eli Lilly reaches insulin development deal with Adocia
AP - Fri Dec 19, 6:16AM CST
INDIANAPOLIS (AP) — Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
LLY: 70.16 (+0.42)
Diabetic Neuropathic Pain - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/qm4xdv/diabetic) has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - Eli Lilly and Company - BioDelivery Sciences - Daiichi Sankyo - Acorda Therapeutics - Astellas Pharma - Glenmark Pharmaceuticals - KunWha Pharmaceutical - Mertiva - Grunenthal - Kyorin Pharmaceutical - Bial - Lohocla Research - Relmada Therapeutics - Sphaera Pharma - Immune Pharmaceuticals - AbbVie - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/qm4xdv/diabetic
IMNP: 1.89 (+0.02), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)
Hypercholesterolemia - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5snkwx/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Amgen - Eli Lilly and Company - Merck & Co - Pfizer - Santaris Pharma - SoluBest - Alnylam Pharmaceuticals - Regeneron Pharmaceuticals - CrystalGenomics - Catabasis Pharmaceuticals - Planet Biotechnology - Zhejiang Hisun Pharmaceutical - Esperion Therapeutics - Progenra - Serometrix - Hanmi Pharmaceuticals - AtheroNova. - Immune Response BioPharma - Agilvax - Michigan Life Therapeutics - LondonPharma - Dybly For more information visit http://www.researchandmarkets.com/research/5s...lesterolem
JNJ: 104.59 (+0.31), ESPR: 35.97 (-0.08), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), REGN: 400.12 (+6.07)
Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
PR Newswire - Fri Dec 19, 12:30AM CST
Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 - ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia's proprietary BioChaperone® technology and is currently in Phase Ib studies.
LLY: 70.16 (+0.42)